



JC10 Rec'd PTO 20 JUN 2005

PCT #5

Attorney Docket # 4830-14PUS

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Diego A. GIANOLIO et al.

Serial No.: 10/511,425

Filed: October 14, 2004

For: Aziridine Compounds and Their Use in Medical  
Devices and Drug Delivery Systems

Examiner:  
Group Art:

I hereby certify that this correspondence is being  
deposited with the United States Postal Service with  
sufficient postage as first class mail in an envelope  
addressed to: Commissioner for Patents, P.O. Box 1450,  
Alexandria, VA 22313-1450, on

June 16, 2005

(Date of Deposit)

Kent H. Cheng

Name of applicant, assignee or Registered Representative

*Kent H Cheng*

Signature

June 16, 2005

Date of Signature

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

SIR:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance  
with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the  
documents listed on the enclosed Form PTO/SB/08a. Copies of the listed documents are also  
enclosed.

It is respectfully requested that the above information be considered by the Examiner  
and that the copy of the enclosed Form PTO/SB/08a be returned indicating that such information  
has been considered.

In accordance with 37 C.F.R §§1.97(g) and (h), the filing of this Information  
Disclosure Statement should not be construed as a representation that a search has been made or  
that information cited is, or is considered to be, material to patentability as defined in §1.56(b),

or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserve(s) the right to prove that the date of publication is in fact different.


If any fees or charges are deemed required at this time in connection with the application, the same may be charged to our Patent and Trademark Office Deposit Account No. 03-2412.

Respectfully submitted,  
COHEN, PONTANI, LIEBERMAN & PAVANE

By: Kent H Cheng  
Kent H. Cheng  
Reg. No. 33,849  
551 Fifth Avenue, Suite 1210  
New York, New York 10176  
(212) 687-2770

Dated: June 16, 2005

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)			<b>Complete if Known</b>		
Application Number			10/511,425		
Filing Date			October 14, 2004		
First Named Inventor			Diego A. GIANOLIO		
Art Unit					
Examiner Name					
Attorney Docket Number			4830-14PUS		
Sheet	1	of	2		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind-Code <sup>5</sup> (if known)				
		NL 6504747	10/17/1996	Dow Chemical Co.		
		FR 1455085	10/14/1996	Dow Chemical Co.		
		GB 2151244	07/17/1985	Balazs et al.		
		GB 2151246	01/21/1987	Balazs et al.		
		SU 1723125	03/30/1992	Vasilevna et al.		
		DE 1243687	07/06/1997	Bestian et al.		
		DE 1270287	06/12/1968	G. Manecke		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ' Applicant's unique citation designation number (optional). ' See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. ' Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ' For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ' Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \* Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for Form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Application Number	10/511,425
		Filing Date	October 14, 2004
		First Named Inventor	Diego A. GIANOLIO
		Art Unit	
		Examiner Name	
Sheet 2 of 2	Attorney Docket Number	4830-14PUS	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		W. McCoull et al., "Recent Synthetic Applications of Chiral Aziridines", <i>Synthesis</i> 2000, No. 10, pp. 1347-1365 (2000).	
		R. D'Agostino, "PE-CVD of Polymer Films: Mechanisms, Chemistry, and Diagnosis", pp. 3-46 (1997).	
		P. Andersson et al., "Enantioselective Addition of Organolithium Reagents to Imines Mediated by C <sub>2</sub> -Symmetric Bis(aziridine) Ligands", <i>Tetrahedron</i> 54, pp 11549-11566 (1998).	
		D. Tanner, et al., "Asymmetric Catalysis via Chiral Aziridines", <i>Acta Chemica Scandinavia</i> , Vol. 50, No. 4, pp. 361-368 (1996).	
		Denmark et al., "Preparation of Chiral Bisoxazolines: Observations on the Effect of Substituents", <i>J. Org. Chem.</i> , Vol. 60, pp. 4884-4892 (1995).	
		Kadorkina et al., <i>Izv. Akad. Nauk SSSR Ser. Khim.</i> 4, pp. 882-885 (1991) Abstract	
		G. Manecke, et al., "Amphotere ion exchanger", <i>Die Makromolekulare Chemie</i> , Vol. 175, pp. 1833-1845 (1974).	
		Watanabe et al., "Synthesis of Aziridine Derivatives from Unsaturated Carboxylic Acid Halides or Chloroformates and Aziridine", <i>Kogyo Kagaku Zasshi</i> , Vol. 72 (6) pp. 1349-1352 (1969).	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form call 1-800-PTO-9100 (1-800-786-9100) and select option 2